Valeo Financial Advisors’s Fulgent Genetics FLGT Stock Holding History

Valeo Financial Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,300	Closed	-$81K	–	558
2022 Q1	$81K	Buy	+1,300	New	+$85.6K	﹤0.01%	583

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Valeo Financial Advisors's FLGT Position: Q3 2022 in Review

Valeo Financial Advisors sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 6,577 shares — an estimated $359K sold.

Valeo Financial Advisors first reported a position in FLGT in Q4 2019 and held it in 11 quarters. The position peaked at $863K in Q4 2021. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

Valeo Financial Advisors reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
Valeo Financial Advisors sold 6,577 Fulgent Genetics shares in Q3 2022, an estimated $359K.
Valeo Financial Advisors first reported a position in Fulgent Genetics in Q4 2019 and held it in 11 quarters.
Valeo Financial Advisors's Fulgent Genetics position peaked at $863K in Q4 2021.
235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Valeo Financial Advisors's 13F filing for Q3 2022, filed 31 Oct 2022.